P612: Lack of seroconversion following COVID-19 vaccination, but not treatment, is an independent risk factor for breakthrough SARS-CoV-2 infection in patients with inflammatory bowel disease: data from ESCAPE - an IG-IBD StudyECCO’23 CopenhagenYear: 2023
Authors: Macaluso, F.S.(1)*;Principi, M.(2);Facciotti, F.(3);Contaldo, A.(4);Todeschini, A.(5);Bezzio, C.(6);Saibeni, S.(6);Castiglione, F.(7);Nardone, O.M.(7);Spagnuolo, R.(8);Fantini, M.C.(9);Riguccio, G.(10);Conforti, F.S.(11);Caprioli, F.A.(11);Viganò, C.(12);Felice, C.(13);Fiorino, G.(14);Correale, C.(15);Bodini, G.(16);Milla, M.(17);Scardino, G.(18);Vernero, M.(19);Desideri, F.(20);Bossa, F.(21);Guerra, M.(21);Ventimiglia, M.(22);Mannino, M.(1);Rizzo, G.(23);Orlando, A.(1);
(1)"Villa Sofia-Cervello" Hospital, IBD Unit, Palermo, Italy;(2)“Aldo Moro” University, Gastroenterology Department, Bari, Italy;(3)Istituto Europeo di Oncologia IRCCS, Dipartimento di Oncologia Sperimentale, Milan, Italy;(4)IRCCS “S. De Bellis”, Gastroenterology 2 Unit-, Castellana Grotte- Bari, Italy;(5)IRCCS Sacro Cuore Don Calabria, IBD Unit, Negrar- Verona, Italy;(6)Rho Hospital- ASST Rhodense, Gastroenterology Unit, Rho- Milan, Italy;(7)Università Federico II di Napoli, Dipartimento di Medicina Clinica e Chirurgia, Napoli, Italy;(8)Università “Magna Graecia”, Dipartimento di Medicina Sperimentale e Clinica-, Catanzaro, Italy;(9)Università di Cagliari, Dipartimento di Scienze Mediche e Sanità Pubblica-, Cagliari, Italy;(10)Ospedale Santa Maria del Prato, UOSD Malattie Infiammatorie Croniche intestinali, Feltre, Italy;(11)Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy;(12)University of Milano-Bicocca, Division of Gastroenterology and Center for Autoimmune Liver Diseases- Department of Medicine and Surgery, Monza, Italy;(13)Ospedale Ca'Foncello, UO Gastroenterologia, Treviso, Italy;(14)IRCCS Ospedale San Raffaele e Università Vita-Salute San Raffaele, Dipartimento di Gastroenterologia ed Endoscopia Digestiva, Milan, Italy;(15)Humanitas Clinical and Research Center, Irccs, Rozzano, Italy;(16)Università di Genova, IRCCS Policlinico San Martino, Genova, Italy;(17)Azienda Ospedaliero-Universitaria Careggi, IBD Referral Center- Gastroenterology Unit, Florence, Italy;(18)Ospedale Valduce, Gastroenterology Depatment, Como, Italy;(19)Department of Medical Sciences- University of Pavia, Gastroenterology Unit, Pavia, Italy;(20)San Maurizio Hospital, Gastroenterology Department-, Bolzano, Italy;(21)“Casa Sollievo della Sofferenza” Hospital- IRCCS, Division of Gastroenterology, San Giovanni Rotondo, Italy;(22)Italian Ministry of Health, Directorate General of Medical Device and Pharmaceutical Service-, Rome, Italy;(23)University of Palermo, Gastroenterology Unit- PROMISE, Palermo, Italy;Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
P613: Switch from intravenous to subcutaneous maintenance infliximab in real world IBD cohortECCO’23 CopenhagenYear: 2023
Authors: Mcgrory, L.(1)*;Goess, C.(1);Lynch, K.(1,2);
(1)Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia;(2)University of Adelaide, Department of Medicine, Adelaide, Australia;
P614: Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohortECCO’23 CopenhagenYear: 2023
Authors: An, Y.K.(1)*;Fernandes, R.(1);Lindsay, N.(2);Khoo, E.(1);Pham, H.(2);Wong, K.F.(2);Thin, L.(3);Goodsall, T.(4);Bryant, R.V.(4);Wright, E.(5);Smith, R.(6);Friedman, A.(6);Begun, J.(1);
(1)Mater Hospital Brisbane, Department of Gastroenterology, Brisbane, Australia;(2)Mater Research Institute, IBD Research Group, Brisbane, Australia;(3)Fiona Stanley Hospital, Department of Gastroenterology, Perth, Australia;(4)The Queen Elizabeth Hospital, Department of Gastroenterology, Adelaide, Australia;(5)St Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(6)Alfred Health, Department of Gastroenterology, Melbourne, Australia;Gastroenterology Network of Intestinal Ultrasound (GENIUS)
P616: Fatigue in pediatric inflammatory bowel diseases – systematic review and rates in a prospective cohortECCO’23 CopenhagenYear: 2023
Authors: Focht, G.(1)*;Turner, S.(2);Carmon, N.(1);Lev-Tzion, R.(1);Orlanski-Meyer, E.(1);Ledder, O.(1);Yogev, D.(1);Assa, A.(3);Turner, D.(1);
(1)Shaare Zedek Medical Center, The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(2)Ben Gurion University of the Negev, Ben Gurion University of the Negev, Beer Sheva, Israel;(3)Shaare Zedek Medcial Center, The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;
P619: Inflammatory bowel disease meets fertility: a physicians and patients surveyECCO’23 CopenhagenYear: 2023
Authors: Vieujean, S.(1)*;De Vos, M.(2);D'Amico, F.(3,4);Paridaens, K.(5);Daftary, G.(6);Peyrin-Biroulet, L.(7,8);Danese, S.(3);
(1)CHU Liège- Sart Tilman, Department of Gastroenterology, Liège, Belgium;(2)UZ Brussel, Centre for Reproductive Medicine, Brussels, Belgium;(3)IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Department of Gastroenterology and Endoscopy, Milan, Italy;(4)Humanitas University- Pieve Emanuele, Department of Biomedical Sciences, Milan, Italy;(5)Ferring International Center S.A., Ferring International Center S.A., Saint-Prex, Switzerland;(6)Ferring Pharmaceuticals A/S, International PharmaScience Center, Kastrup, Denmark;(7)University of Lorraine- CHRU-Nancy, Department of Gastroenterology, Nancy, France;(8)University of Lorraine, Inserm- NGERE, Nancy, France;
P620: Can ustekinumab trough and antidrug antibody levels post induction predict treatment failure?ECCO’23 CopenhagenYear: 2023
Authors: Mccrossan, M.(1)*;O'Moráin, N.(1,2);Kumar, L.(1,2);Rowan, C.(1);Sheridan, J.(1);Cullen, G.(1,2);Doherty, G.(1,2);Mulcahy, H.(1,2);
(1)St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland;(2)University College Dublin, School of Medicine & Medical Science, Dublin, Ireland;
P621: Combination treatment of biologics with immunomodulator increases risk of infection after discharge in biologics naive steroid refractory acute severe ulcerative colitis patient: A KASID multicenter studyECCO’23 CopenhagenYear: 2023
Authors: Kim, S.J.(1)*;Lee, J.(1);Kim, D.H.(2);Park, S.H.(3);Kim, E.S.(4);Kim, K.O.(5);Lee, Y.J.(6);Song, E.M.(7);Kim, D.S.(8);
(1)College of Medicine- Chosun University, Internal Medicine, Gwangju, Korea- Republic Of;(2)Chonnam National University Hospital and Medical School, Internal Medicine, Gwangju, Korea- Republic Of;(3)Asan Medical Center, Internal Medicine, Seoul, Korea- Republic Of;(4)School of Medicine- Kyungpook National University, Internal Medicine, Daegu, Korea- Republic Of;(5)Yeungnam University hospital, Internal Medicine, Deagu, Korea- Republic Of;(6)Keimyung University Hospital, Internal Medicine, Daegu, Korea- Republic Of;(7)Ewha Womans University Seoul Hospital, Internal Medicine, Seoul, Korea- Republic Of;(8)Konyang University Hospital, Internal Medicine, Daejeon, Korea- Republic Of;IBD Research Group in Korean Association for the Study of the Intestinal Diseases (KASID)
P623: Mucosal eosinophils as markers of post-induction vedolizumab response in paediatric Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Musto, F.(1)*;Ranalli, M.(2);Giordano, C.(3);Bianchi, E.(2);Veraldi, S.(4);Oliva, S.(5);D'Arcangelo, G.(2);Aloi, M.(2);
(1)Sapienza University, Paediatric Gastroenterology Unit- Department of Maternal and Child Health, Roma, Italy;(2)Sapienza University, Paediatric Gastroenterology Unit- Department of Maternal and Child Health, Rome, Italy;(3)Sapienza University, Department of Radiology- Oncology and Pathology, Rome, Italy;(4)Sapienza University, Department of Anatomical- Histological- Forensic and Locomotor Apparatus Sciences, Rome, Italy;(5)Sapienza University, Paediatric Gastroenterology Unit-Department of Maternal and Child Health, Rome, Italy;
P624: Investigating the symptom burden among European patients with moderate-to-severe Crohn's disease using a real-world surveyECCO’23 CopenhagenYear: 2023
Authors: BurischPhD, J.(1)*;Hart, A.(2);Sturm, A.(3);Knight, H.(4);Rudolph, C.(5);Meadows, R.(4);Oortwijn, A.(5);Weatherby, S.(4);Rolph, R.(6);Dawod, F.(4);Armuzzi, A.(7);
(1)Hvidovre University Hospital, Department of Gastroenterology, Hvidovre, Denmark;(2)St Mark's Hospital, IBD Unit, Harrow, United Kingdom;(3)German Red Cross Hospital Berlin, Department of Internal Medicine - Gastroenterology, Berlin, Germany;(4)Adelphi Real World, Adelphi Real World, Bollington, United Kingdom;(5)Galapagos NV, Medical Affairs Department, Leiden, The Netherlands;(6)Galapagos NV, Medical Affairs Department, Mechelen, Belgium;(7)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;
P625: Randomized controlled trial on the effect of megaboluses of intravenous corticosteroids added to oral corticosteroids in the treatment of moderately active ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Llaó, J.(1);Martín-Arranz, E.(2);Zabana, Y.(3);Navarro-Llavat, M.(4);Garcia-Planella, E.(5);Busquets, D.(6);Monfort, D.(7);Pineda, J.R.(8);Gutiérrez, A.(9);Villoria, A.(10);Menchén, L.(11);Bastida, G.(12);García-Alonso, F.J.(13);Rivero, M.(14);Chaparro, M.(15);Riestra, S.(16);Merino, O.(17);Rodríguez-Lago, I.(18);Barreiro-de-Acosta, M.(19);Domènech MoralPhD, E.(20)*;
(1)Xarxa Assistencial Althaia, Gastroenterology, Manresa, Spain;(2)H..U.La Paz, Gastroenterology, Madrid, Spain;(3)H.U.Mútua Terrassa & CIBEREHD, Gastroenterology, Terrassa, Spain;(4)H.Moisès Broggi, Gastroenterology, Sant Joan Despí, Spain;(5)H.. de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(6)H.U. Josep Trueta, Gastroenterology, Girona, Spain;(7)Consorci Sanitari de Terrassa, Gastroenterology, Terrassa, Spain;(8)H. Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(9)H. .G.U. Dr Balmis & ISABIAL, Gastroenterology, Alicante, Spain;(10)Consorci Sanitari Parc Taulí & CIBEREHD, Gastroenterology, Sabadell, Spain;(11)H.U. Gregorio Marañón & CIBEREHD, Gastroentrology, Madrid, Spain;(12).Universitari i Politècnic La Fe, Gastroenterology, Valencia, Spain;(13)H.U.Río Hortega, Gastroenterology, Valladolid, Spain;(14)H.U. Marqués de Valdecilla & IDIVAL, Gastroenterology, Santander, Spain;(15)H.U.La Princesa & CIBEREHD, Gastroenterology, Madrid, Spain;(16)H.U. Central Asturias, Gastroenterology, Oviedo, Spain;(17)H.Cruces, Gastroenteorology, Bilbao, Spain;(18)H. Galdakao, Gastroenterology, Galdakao, Spain;(19)Complejo hospitalario de Santiago, Gastroenterology, Santiago de Compostela, Spain;(20)Hospital Universitario Germans Trias i Pujol and CIBEREHD, Gastroenterology, Badalona, Spain;
P627: HLA DQA1*05 was not associated to primary non-response or loss of response to first anti-TNF in real world Inflammatory Bowel Disease patients.ECCO’23 CopenhagenYear: 2023
Authors: Pascual Oliver, A.(1)*;Cuarán, C.(1);Casas-Deza, D.(1,2);García-López, S.(1,2);Corsino-Roche, P.(1,2);Sierra Moros, E.(1);Julián-Gomara, A.B.(1);Vicente-Lidón, R.(1);
(1)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(2)Instituto de Investigación Sanitaria de Aragón, Gastroenterology, Zaragoza, Spain;
P628: Tofacitinib in pediatric ulcerative colitis: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHANECCO’23 CopenhagenYear: 2023
Authors: Ledder, O.(1)*;Dubinsky, M.(2);Dolinger, M.(2);Fatima, A.(3);Suskind, D.(4);Scarlett, J.(4);Röeser, D.(5);Shouval, D.(6);Meyer, G.(7);Molle Rios, Z.(7);Pujol, G.(8);Lozano, A.(8);Kolho, K.L.(9);Rohani, P.(10);Hussey, S.(11);de Mejj, T.(12);Ayers, T.(13);Navas López, V.M.(14);Turner, D.(1);Tzivinikos, C.(15);
(1)Shaare Zedek Medical Center, Juliet Keidan Institute of Paediatric Gastroenterology, Jerusalem, Israel;(2)Icahn School of Medicine at Mount Sinai, Susan and Leonard Feinstein IBD Clinical Center, New York, United States;(3)Beaumont Children's Hospital, Pediatric Gastroenterology Department, Rochester, United States;(4)Seattle Children's Hospital Inflammatory Bowel Disease Center, Division of Gastroenterology, Seattle, United States;(5)Copenhagen University Hospital, Pediatric Department, Hvidovre, Denmark;(6)Schneider Children's Medical Center of Israel, Institute of Gastroenterology Nutrition and Liver Diseases, Petach Tikva, Israel;(7)Nemours Children's Hospital Wilmington, Division of Pediatric Gastroenterology, Wilmington, United States;(8)Hospital Sant Joan de Deu, Pediatric Gastroenterology- Hepatology and Nutrition Department, Barcelona, Spain;(9)Children's Hospital- Helsinki University, Pediatric Gastroenterology Department, Helsinki, Finland;(10)Children Medical Center- University of Medical Sciences, Pediatric Gastroenterology and Hepatology Research Center, Tehran, Iran- Islamic Republic Of;(11)Royal College of Surgeons of Ireland and University College Dublin, National Children's Research Centre, Dublin, Ireland;(12)Department of Pediatric Gastroenterology-, AG&M Research Institute- Amsterdam UMC, Amsterdam, The Netherlands;(13)Division of Pediatric Gastroenterology, Arkansas Children's Hospital- UAMS, Little Rock, United States;(14)IBIMA- Hospital Regional Universitario de Málaga, Pediatric Gastroenterology and Nutrition Unit, Málaga, Spain;(15)Paediatric Gastroenterology Department, Al Jalila Children's Specialty Hospital- Mohammed Bin Rashid University, Dubai, United Arab Emirates;
P629: Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatmentECCO’23 CopenhagenYear: 2023
Authors: Ylisaukko-oja, T.(1);Af Björkesten, C.G.(2)*;Erbel, A.(2);Nuutinen, H.(3);Jussila, A.(4);Molander, P.(2);Koskela, R.(5);Blomster, T.(5);Pajala, M.(6);Ilus, T.(4);Haiko, P.(7);Kovac, B.(7);Silvola, S.(7);Smith, S.(1);Jokelainen, J.(1);Sipponen, T.(2);
(1)MedEngine Oy, Medical Data Science, Helsinki, Finland;(2)University of Helsinki and Helsinki University Hospital, Abdominal Center- Gastroenterology, Helsinki, Finland;(3)Turku University Hospital, Division of Gastroenterology- Department of Medicine, Turku, Finland;(4)Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland;(5)Oulu University Hospital, Department of Medicine- Division of Gastroenterology, Oulu, Finland;(6)Kuopio University Hospital, Department of Internal Medicine, Kuopio, Finland;(7)Takeda Oy, Takeda Oy, Helsinki, Finland;
P630: Upadacitinib Improves Clinical Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional TherapiesECCO’23 CopenhagenYear: 2023
Authors: Schreiber, S.W.(1)*;Lim, A.(2);Lacerda, A.P.(3);Allegretti, J.R.(4);Watanabe, K.(5);Lukin, D.(6);Dubenco, E.(3);Ford, S.(3);Oomen, J.(3);Zhou, Q.(3);Liu, J.(3);Louis, E.(7);
(1)University Hospital Schleswig-Holstein- Christian Alrechts University, Department Internal Medicine, Kiel, Germany;(2)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;(3)AbbVie, none, North Chicago, United States;(4)Brigham and Women's Hospital, Division of Gastroenterology- Department of Internal Medicine, Boston, United States;(5)Hyogo Medical University, Division of Gastroenterology and Hepatology- Department of Internal Medicine-, Hyogo, Japan;(6)New York Presbyterian/Weill Cornell Medical Center, Department of Gastroenterology and Hepatology, New York, United States;(7)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology Department, Liège, Belgium;
P631: Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn's Disease (CD): Results from a large multinational prospective observational studyECCO’23 CopenhagenYear: 2023
Authors: Louis, E.(1)*;Sebastien, S.(2);Siegmund, B.(3);Bossuyt, P.(4);Danese, S.(5);de Boer, N.(6);Loftus, E.(7);Moum, B.(8);Peyrin-Biroulet, L.(9);Schreiber, S.(10);Zhou, J.(11);Wernicke, J.(11);Angellotti, E.(12);Siegel, C.(13);
(1)University of Liège, CHU Liège, Liège, Belgium;(2)Hull University Teaching Hospital, Gastroenterology, Hull, United Kingdom;(3)Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany;(4)Imelda GI Clinical Research Center, Imelda General Hospital, Bonheiden, Belgium;(5)University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;(6)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology- AGEM Research Institute, Amsterdam, The Netherlands;(7)Mayo Clinic College of Medicine and Science, Gastroenterology, Rochester- MN, United States;(8)Østfold Hospital Trust & University of Oslo, Gastroenterology, Oslo, Norway;(9)Nancy University Hospital, Gastroenterology, Nancy, France;(10)University Hospital Schleswig-Holstein, Gastroenterology, Kiel, Germany;(11)Takeda, Takeda, Cambridge- MA, United States;(12)Takeda, Takeda, Cambridge- MA, United Kingdom;(13)Dartmouth Hitchcock Medical Center-, Gastroenterology, Lebanon- NH, United States;
